ROSEN, A TOP RANKED FIRM, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important December 29 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RTX, RTN
04 déc. 2020 16h30 HE
|
The Rosen Law Firm PA
NEW YORK, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE:...
ROSEN, TRUSTED INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Raytheon Technologies Corporation – RTX, RTN
29 oct. 2020 20h17 HE
|
The Rosen Law Firm PA
NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Raytheon...
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain
28 sept. 2020 09h00 HE
|
Sorrento Therapeutics, Inc.
Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months...
Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial
27 févr. 2020 15h30 HE
|
Sorrento Therapeutics, Inc.
Fourteen subjects with advanced cancer pain received epidural RTX (04 to 15 ug)Most common treatment-related adverse event was transient post-procedure related painThree subjects at the higher doses...
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences
27 janv. 2020 07h00 HE
|
Sorrento Therapeutics, Inc.
Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to...
Dr. Henry Ji to Participate in Multiple Investment Conferences in September 2019 to Provide Corporate Updates
05 sept. 2019 08h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in multiple investment...
Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study
15 avr. 2019 04h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin...